Kolorektal Karsinomlarda Her2 Amplifikasyonu

Nowak JA. HER2 in Colorectal Carcinoma: Are We There yet?. Surg Pathol Clin. 2020;13(3):485-502. doi:10.1016/j.path.2020.05.007

Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, et al. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci. 2020;21(22):8529. doi:10.3390/ijms21228529

Stanowicka-Grada M, Senkus E. Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer. Curr Treat Options Oncol. 2023;24(11):1633-1650. doi:10.1007/s11864-023-01137-5

Angerilli V, Parente P, Campora M, et al. HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective. J Clin Pathol. 2023;76(12):815-821. doi:10.1136/jcp-2023-208767

May M, Raufi AG, Sadeghi S, et al. Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. Oncologist. 2021;26(8):640-646. doi:10.1002/onco.13800

Jafari M, Laraqui A, Baba W, et al. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa. BMC Cancer. 2022;22(1):1142. Published 2022 Nov 7. doi:10.1186/s12885-022-10235-w

Shayeb AM, Kurzrock R, Adashek JJ, et al. Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies. JCO Precis Oncol. 2023;7:e2200604. doi:10.1200/PO.22.00604

Memon R, Prieto Granada CN, Harada S, et al. Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression/gene amplification in breast cancer in the modern age: A single institution experience and pooled literature review study. Clin Breast Cancer. 2022;22:e123–e133. doi: 10.1016/j.clbc.2021.05.004.

Pogue-Geile KL, Kim C, Jeong JH, et al. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst. 2013;105:1782–1788. doi: 10.1093/jnci/djt321.

Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations [published correction appears in Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034.]. Cell. 2018;173(2):371-385.e18. doi:10.1016/j.cell.2018.02.060

Robinson HR, Messersmith WA, Lentz RW. HER2-Positive Metastatic Colorectal Cancer. Curr Treat Options Oncol. 2024;25(5):585-604. doi:10.1007/s11864-024-01183-7

Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481-1491. doi:10.1038/modpathol.2015.98

Martianov AS, Mitiushkina NV, Ershova AN, et al. KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas. Int J Mol Sci. 2023;24(5):4868. Published 2023 Mar 2. doi:10.3390/ijms24054868

Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358-1373. doi:10.1002/cncr.31125

Xia D, Kuo F, Hughes M, et al. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer. Am J Clin Pathol. 2024;161(5):436-442. doi:10.1093/ajcp/aqad167

Ross DS, Zehir A, Cheng DT, et al. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay [published correction appears in J Mol Diagn. 2017 May;19(3):485. doi: 10.1016/j.jmoldx.2017.02.001.]. J Mol Diagn. 2017;19(2):244-254. doi:10.1016/j.jmoldx.2016.09.010

Moussa M, Badawy A, Helal N, et al. Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions. Asian Pac J Cancer Prev. 2020;21(8):2357-2366. Published 2020 Aug 1. doi:10.31557/APJCP.2020.21.8.2357

Zhang XH, Zhou JQ, Wei Q, et al. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer. Discov Med. 2024;36(186):1477-1485. doi:10.24976/Discov.Med.202436186.137

Lee SM, Oh H. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification. Sci Rep. 2024;14(1):11432. Published 2024 May 19. doi:10.1038/s41598-024-62096-x

Conradi L.C., Styczen H., Sprenger T., et. al. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol. 2013; 37: pp. 522-531. doi:10.1097/PAS.0b013e318272ff4d

Chen N, He L, Zou Q, Deng H. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions. Biochem Pharmacol. 2024;223:116101. doi:10.1016/j.bcp.2024.116101

Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496-508. doi:10.1016/S1470-2045(23)00150-X

Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009;8(11):2983-2991. doi:10.1158/1535-7163.MCT-09-0820

Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508-523. doi:10.1158/2159-8290.CD-11-0109

Mauri D, Kamposioras K, Matthaios D, et al. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach. Oncol Res Treat. 2022;45(4):216-221. doi:10.1159/000521845